Mielóma multiplex: vizsgálatok itt: Svédország

In Svédország 22 Also abroad 703

22 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.

4. fázisTaking people
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Where
Lund, Uppsala
Életkor
18 év and over
People
295 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05201781 · EU 2023-505530-10-00
3. fázisTaking people
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Where
Falun, Huddinge, Lund, Orebro
Életkor
18 év and over
People
1590 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00
2. fázisTaking people
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Where
Falun, Gothenburg, Lund, Stockholm, Uppsala
Életkor
18 év and over
People
230 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07589634
3. fázisTaking people
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Where
Goteborg, Huddinge, Lund
Életkor
18 év and over
People
440 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00
1/2. fázisTaking people
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Where
Boras, Goteborg, Huddinge
Életkor
18 év and over
People
325 worldwide
Run by
AbbVie
See details and how to joinNCT06953960 · EU 2024-517140-65-00
2. fázisCsak meghívásos
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Where
Luleå
Életkor
18 év and over
People
70 worldwide
Run by
Sanofi
See details and how to joinNCT05669989
2. fázisTaking people
Phase 2 Randomized, Double-blind, Placebo-controlled Study of Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma
Where
Falun, Goteborg, Huddinge, Lund, Uppsala
Életkor
18 év and over
People
123 worldwide
Run by
Janssen Cilag International
See details and how to join2025-524793-42-00 · EU 2025-524793-42-00
3. fázisNot yet taking people in Svédország
A trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma
Where
Goteborg, Huddinge, Lund
Életkor
18 év and over
People
234 worldwide
Run by
AstraZeneca AB
See details and how to join2025-524014-29-00 · EU 2025-524014-29-00
No phaseTaking people
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
Where
Gothenburg, Jönköping, Stockholms, Uddevalla
Életkor
18 év and over
People
900 worldwide
Run by
Janssen-Cilag Ltd.
See details and how to joinNCT06285318
3. fázisTaking people
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Where
Boras, Falun, Goteborg, Linkoping, Luleå, Lund, Orebro
Életkor
18 év and over
People
893 worldwide
Run by
Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00
3. fázisTaking people
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Where
Falun, Huddinge, Orebro
Életkor
18 év and over
People
492 worldwide
Run by
Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00
1/2. fázisTaking people
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Where
Huddinge
Életkor
18 év and over
People
123 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT05714839 · EU 2022-501941-63-00
3. fázisTaking people
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Where
Gothenburg, Huddinge, Lund
Életkor
18 év and over
People
750 worldwide
Run by
AstraZeneca
See details and how to joinNCT07764978
1. fázisTaking people
A Study in Leukemia Patients With Karonudib
Where
Huddinge, Örebro
Életkor
18 év to 75 év
People
50 worldwide
Run by
Thomas Helleday Foundation
See details and how to joinNCT04077307
1/2. fázisTaking people
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Where
Boras, Goteborg, Huddinge
Életkor
18 év and over
People
88 worldwide
Run by
AbbVie Deutschland GmbH & Co. KG
See details and how to join2025-525105-20-00 · EU 2025-525105-20-00
1/2. fázisTaking people
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Where
Stockholm
Életkor
18 év and over
People
250 worldwide
Run by
CellCentric Ltd.
See details and how to joinNCT04068597
3. fázisTaking people
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Where
Lund
Életkor
18 év and over
People
1000 worldwide
Run by
European Myeloma Network B.V.
See details and how to joinNCT06932562 · EU 2024-519827-16-00
No phaseTaking people
Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
Where
Lund
Életkor
18 év and over
People
75 worldwide
Run by
Takeda
See details and how to joinNCT05879757
2. fázisTaking people
Discontinuation Outcome in Multiple Myeloma after BCMA-CD3 treatment
Where
Boras, Falun, Goteborg, Halmstad, Helsingborg, Huddinge, Jonkoping, Linkoping, Lund, Orebro, Trollhattan, Umea, Uppsala, Varberg
Életkor
18 év and over
People
200
Run by
Vaestra Goetalandsregionen
See details and how to join2025-524022-18-00 · EU 2025-524022-18-00
1/2. fázisTaking people
Study of ODX (OsteoDex) in Multiple Myeloma
Where
Stockholm, Uddevalla
Életkor
18 év and over
People
12
Run by
DexTech Medical AB
See details and how to joinNCT06616389
No phaseTaking people
Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
Where
Uppsala
Életkor
18 év and over
People
100
Run by
Uppsala University
See details and how to joinNCT06245629
2. fázisTaking people
Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma
Where
Stockholm
Életkor
18 év and over
People
62
Run by
Karolinska Institutet
See details and how to joinNCT04558931